Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06385288
Other study ID # 268/2021BO2
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 21, 2021
Est. completion date July 21, 2031

Study information

Verified date July 2023
Source University Hospital Tuebingen
Contact Franziska Eckert, MD, Prof.
Phone +49 7071 29
Email franziska.eckert@med.uni-tuebingen.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

"Blood and Tissue Extraction for Immunological Examinations During Neoadjuvant Therapy of Soft Tissue Sarcoma" is a prospective study with additional translational research using preoperative and postoperative tissue, blood sampling and advanced imaging.


Description:

All patients (> 18 Years) with histologically confirmed high-risk soft tissue sarcoma eligible for neoadjuvant multimodal therapy (including radiotherapy +/- concomitant and sequential chemotherapy +/- hyperthermia as well as surgery) are screened for the study. Neoadjuvant therapy consists of 50-50.4 Gy in 25-28 fractions. Additional concomitant or sequential chemotherapy may be applied in selected cases (young patients, high-grade tumors). Additional hyperthermia concomitant to neoadjuvant radiotherapy is applied in selected cases if not contraindicated. Preoperative tissue sampling to generate primary tumor cell lines in additional translational research is performed in each patient with a lesion suspect for soft tissue sarcoma and eligible for multimodal therapy. Primary cell lines are analyzed biologically (growth pattern, radioresistance, migration, molecular markers RT-PCR, immunological properties such as immunogenic cell death, lysis by cellular immunotherapies such as CAR-NK cells. Postoperative tumor tissues are additionally analyzed for immune cell mapping using complex immunohistochemistry. Biopsy and resection should include proteome analysis and DNA sequencing (only of the tumor tissue, not normal tissue). Additional immunological monitoring (including cellular immune status, serum marker e.g. cell free DNA, HMGB1) is performed using blood sampling with in total 4 blood controls (25 ml each, before neoadjuvant radiotherapy, during the second and last week of radiotherapy as well as before surgery). In patients treated with concomitant MR-guided hyperthermia, weekly MR-imagine is performed. Follow-up is carried out as part of the oncological controls over 5 years. The overall study is planned over a period of 5 years (interventional part), additional 5 years follow-up period.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date July 21, 2031
Est. primary completion date July 21, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Planned histological confirmation for especially high-risk soft tissue sarcoma via open Sampling - Indication for neoadjuvant multimodal therapy (radiation and locoregional Hyperthermia, optionally with simultaneous chemotherapy) - Planned resection of a department of the CWS - Age > 18 years - Ability to consent - Additionally for imaging study: Treatment on the combined MR hyperthermia device Exclusion Criteria: - Age < 18 years - Poor understanding (language etc.) - Lack of reconnaissance ability

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Blood and tissue collection for immunological studies, advanced imaging.
Blood and tissue collection for immunological studies under neoadjuvant Therapy of soft tissue sarcomas. Prospective data collection and translational accompanying research on standard therapy. Use of tissue, blood samples and advanced imaging.
neoadjuvant Therapy
neoadjuvant Therapy

Locations

Country Name City State
Germany University Hospital Tuebingen Tübingen Baden-Württemberg

Sponsors (1)

Lead Sponsor Collaborator
University Hospital Tuebingen

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Description of the cellular immune status via flow-cytometrie from collected blood samples Blood samples are taken on the days of simulation-CT, first and third week of the radiation therapy, as well as before surgery. 5 years of recruitment, 5 years follow-up
Primary Description of the cellular immune status on tissue samples ussing komplex immunohistochemie Tissue samples are taken as incisional biopsie as well as in the tumor tissue after the surgery 5 years of recruitment, 5 years follow-up
Primary Measurement of the cellular free DNA from collected blood samples Blood samples are taken on the days of simulation-CT, first and third week of the radiation therapy, as well as before surgery. 5 years of recruitment, 5 years follow-up
Primary Measurement of HMGB1 from collected blood samples Blood samples are taken on the days of simulation-CT, first and third week of the radiation therapy, as well as before surgery. 5 years of recruitment, 5 years follow-up
Primary Evaluation of morphological tumor characteristics (size, diffusion) with weekly MRIs Weekly MRIs during neoadjuvant radiation therapy 5 years of recruitment, 5 years follow-up
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04577014 - Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma Phase 1/Phase 2
Recruiting NCT04656262 - Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients Phase 3
Recruiting NCT03077178 - Impact of Locoregional Treatment of Soft Tissue Sarcoma on Status of Patients Aged 70 Years and Over N/A
Not yet recruiting NCT06110650 - A Study of Surufatinib in the Treatment of Advanced Soft Tissue Sarcoma N/A
Terminated NCT03735758 - Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib Phase 4
Not yet recruiting NCT03951571 - Efficacy and Safety of Anlotinib in Adjuvant Therapy for High-grade Soft Tissue Sarcoma Phase 2
Enrolling by invitation NCT03134742 - Radiation Effects on Bone
Not yet recruiting NCT06252727 - Fluorescent Aided Resection and Evaluation of Soft Tissue Sarcomas (FLARES) Phase 1
Recruiting NCT04617327 - Pre-operative RadiothErapy for Soft Tissue SarcOmas N/A
Recruiting NCT05116254 - Sarcomas and DDR-Inhibition; a Combined Modality Study Phase 1
Active, not recruiting NCT03526679 - Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma Phase 1/Phase 2
Recruiting NCT04008238 - Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients N/A
Recruiting NCT04095208 - Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study Phase 2
Recruiting NCT04330456 - Combined Treatment of Patients With Soft Tissue Sarcoma Including Preoperative Stereotactic Radiation Therapy and Postoperative Conformal Radiation Therapy N/A
Completed NCT03833037 - Study of a Cohort of Cases of Synovial Sarcoma Treated in the Orthopedic Surgery and Traumatology Department of the Hospital de Sant Pau Between 1983 and 2016
Completed NCT03056599 - Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma Phase 1
Recruiting NCT05961761 - Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients Phase 2
Recruiting NCT06273852 - A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors Early Phase 1
Recruiting NCT05182164 - Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas Phase 2
Withdrawn NCT03104335 - Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial Phase 2